Phase III Failure Bruises Eli Lilly’s Blissful 2014 Outlook

Washington Drug Letter
A A
Eli Lilly’s plans for strong sales growth in 2014 have been set back, with the drugmaker saying Thursday its promising depression treatment edivoxetine has failed in late-stage testing.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00